Efficacy and Safety of DaxibotulinumtoxinA for Injection Over Successive Treatments in Adults With Cervical Dystonia in the Phase 3 ASPEN-1 and ASPEN-OLS Trials

被引：0
|
作者：
Comella, Cynthia [1 ]
Barbano, Richard [2 ]
Singer, Carlos [3 ]
Vasquez, Alberto [4 ]
Gross, Todd M. [5 ]
Vitarella, Domenico [5 ]
机构：
[1] Rush Univ, Med Ctr, Chicago, IL USA
[2] Univ Rochester, Rochester, NY USA
[3] Univ Miami, Miller Sch Med, Miami, FL USA
[4] Suncoast Neurosci Associates, St Petersburg, FL USA
[5] Revance Therapeut Inc, 1222 Demonbreun St,Suite 2000, Nashville, TN USA
来源：
TOXICON | 2024年 / 237卷
关键词：
Dystonia; DaxibotulinumtoxinA; Spasmodic torticollis; Immunogenicity;
D O I：
10.1016/j.toxicon.2024.107383
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 26 条
  • [21] Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
    Thaci, Diamant
    Simpson, Eric L.
    Deleuran, Mette
    Kataoka, Yoko
    Chen, Zhen
    Gadkari, Abhijit
    Eckert, Laurent
    Akinlade, Bolanle
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 94 (02) : 266 - 275
  • [22] Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase 3 clinical trials at 52 weeks
    Paller, Amy S.
    Mendes-Bastos, Pedro
    Eichenfield, Lawrence F.
    Soong, Weily
    Lio, Peter
    Prajapati, Vimal H.
    Platt, Andrew M.
    Raymundo, Eliza
    Liu, John
    Ladizinski, Barry
    Thyssen, Jacob P.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [23] Efficacy and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Measure Up 1, Measure Up 2, and AD Up Phase 3 Clinical Trials at 52 Weeks
    Paller, Amy
    Mendes-Bastos, Pedro
    Eichenfield, Lawrence
    Soong, Weily
    Lio, Peter
    Prajapati, Vimal
    Platt, Andrew
    Liu, John
    Ladizinski, Barry
    Thyssen, Jacob
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB157 - AB157
  • [24] Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
    Orkin, Chloe
    Molina, Jean-Michel
    Cahn, Pedro
    Lombaard, Johannes
    Supparatpinyo, Khuanchai
    Kumar, Sushma
    Campbell, Havilland
    Wan, Hong
    Teal, Valerie
    Xu, Zhi Jin
    Asante-Appiah, Ernest
    Sklar, Peter
    Teppler, Hedy
    Lahoulou, Rima
    LANCET HIV, 2024, 11 (02): : e75 - e85
  • [25] EFFICACY AND SAFETY OF LEFAMULIN VS MOXIFLOXACIN FOR ATYPICAL RESPIRATORY PATHOGENS IN ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA: POOLED RESULTS FROM THE LEFAMULIN EVALUATION AGAINST PNEUMONIA (LEAP) 1 AND LEAP 2 DOUBLE-BLIND NONINFERIORITY PHASE-3 CLINICAL TRIALS
    Shorr, Andrew
    Schranz, Jennifer
    Goldberg, Lisa
    Paukner, Susanne
    Alexander, Elizabeth
    Moran, Gregory
    Sandrock, Christian
    Gelone, Steven
    CHEST, 2019, 156 (04) : 1133A - 1134A
  • [26] Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naive and -experienced, virologically-suppressed adults living with HIV-1
    Huhn, Gregory D.
    Wilkin, Aimee
    Mussini, Cristina
    Spinner, Christoph D.
    Jezorwski, John
    El Ghazi, Mohsine
    Van Landuyt, Erika
    Lathouwers, Erkki
    Brown, Kimberley
    Baugh, Bryan
    HIV RESEARCH & CLINICAL PRACTICE, 2021, 21 (06) : 151 - 167
123